The hemp industry is still young and evolving! Naturally, there are still challenges with issues such as the unsteady supply chain and the immaturity of after-market processing. But there’s so much more balancing out the positive side of the equation and the industry mechanics and operations continue to improve with every growing season.
From the perspective of the USDA, hemp is regarded as a kind of “wonder crop”. Hemp can improve soil health, support bioremediation in areas where toxins have built up. It’s an ecological bonanza that will positively impact production and jobs in the food, fuel, and fiber industries.
The consumer point of view is equally sunny, especially since the onset of the pandemic. The everyday stresses precipitated by COVID and related restrictions shifted focus for many seeking healthy coping solutions such as CBD. Now, there is a growing interest in a lesser-known cannabinoid – CBG – that is also being studied intensively for its therapeutic potential.
As we all know, hemp contains cannabinoids in varying degrees. THC (a psychoactive) and CBD are
probably the best known to consumers. But a lesser-known cannabinoid – CBG – is starting to gain
interest and popularity. While THC and CBD are found in fairly significant quantities in hemp (around 20-
30%), CBG is rarer – as low as just 1% in some strains. Accordingly, this makes CBG products more costly. There also appears to be a distinct difference between what CBG and CBD can do therapeutically; in other words, CBG is not just the same cannabinoid by a different name.
CBG is being studied for its potential pharmaceutical use in treating IBS, glaucoma, and Huntington’s Disease. It also shows promise because of its antibacterial properties, soothing neurological properties, and its suspected potential to block receptors that cause cancer cell growth. While there is much to be
learned and confirmed about these possible benefits, there is certainly evidence-based cause to be optimistic about where the research is going. As clinical trials and studies continue, we are hopeful that the growing data base will expand the consumer market for CBG-based products.
CBG and Hemp Growers
The post-production marketplace also appears full of potential. Based on the speedy growth of CBD-
infused products — foods, topicals, supplements, pet products, flowers, etc. – it seems likely that CBG
could follow a similar path as post-harvest processes and the consumer awareness continue to mature.
Pharmaceutical shoppers seem keenly interested in both non-intoxicating health-related products and
environmentally responsible products – CBG aligns with both motivations.
Fair to say that science, hemp economics, and consumer demand are fueling a well-placed, growing
interest in CBG hemp agriculture.
Let’s Get Growing with Some High-quality CBG Hemp Seed
If this rosy outlook for CBG sounds appealing to you and you’re ready to give it a go, we have just the strain for you: Minnesota G S1 Feminized High CBG Hemp Seed, now available through Cheyenne Mountain Seed Company. With two to five pounds of yield per plant, this robust strain packs an unbeatable one-two punch with exceptionally low THC levels (never exceeding .3%, regardless of maturity) and a whopping 16% CBG under optimal growing conditions. The plants grow to five feet in height, plantable on four- to five-foot centers, with a September/October harvest window. We’d love to answer your questions and help you get started with the dynamite new seed product! Give us a call now at 719.217.0207.